Theravance Biopharma earnings were $13.0M for the trailing 12 months ending Jun 30, 2025, with N/A growth year over year. The latest TBPH earnings report on Jun 30, 2025 announced Q2 2025 earnings of $54.8M, down 503.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, TBPH reported annual earnings of -$56.4M, with 2.2% growth. The next TBPH earnings date is Nov 5, 2025.
TBPH past earnings growth
How has TBPH's earnings growth performed historically?
Theravance Biopharma Earnings Reports & History FAQ
What were Theravance Biopharma's earnings last quarter?
On TBPH's earnings call on Invalid Date, Theravance Biopharma (NASDAQ: TBPH) reported Q2 2025 earnings per share (EPS) of $1.09, up 420.59% year over year. Total TBPH earnings for the quarter were $54.84 million. In the same quarter last year, Theravance Biopharma's earnings per share (EPS) was -$0.34.
The next TBPH earnings call is Invalid Date. Add TBPH to your watchlist to be reminded of Theravance Biopharma's next earnings date.
Is Theravance Biopharma profitable or losing money?
As of the last Theravance Biopharma earnings report, Theravance Biopharma is currently profitable. Theravance Biopharma's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $13.03 million, a 128.54% decrease year over year.
What was TBPH's earnings growth in the past year?
As of Theravance Biopharma's earnings date in Invalid Date, Theravance Biopharma's earnings has grown year over year. TBPH earnings in the past year totalled $13.03 million.
What are Theravance Biopharma's earnings expectations?
The current EPS estimate for Theravance Biopharma's earnings report in Invalid Date is -$0.13.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.